Immunotherapy combinations for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer that has not been treated with systemic therapy yet.
- Your cancer must have some clear cell features (most common type of kidney cancer).
- You need to be in generally good health (able to care for yourself) and willing to provide a tumor sample.
- You cannot have certain autoimmune conditions or be on high doses of steroids.
- You must agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
This trial tests a new combination of two drugs (envafolimab and axitinib) as the first treatment for advanced kidney cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a new immunotherapy drug (cemiplimab), either alone or combined with another drug (fianlimab), after targeted radiation (SBRT) to kill cancer cells. It is for people with advanced clear cell kidney cancer who have few spots of spread and have not had many prior treatments.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
Hear when a new Advanced Renal Cell Carcinoma (aRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.